Biodesix (BDSX) Total Liabilities (2019 - 2026)

Biodesix (BDSX) has 8 years of Total Liabilities data on file, last reported at $85.5 million in Q1 2026.

• Quarterly Total Liabilities rose 13.73% year-over-year to $85.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $85.5 million (up 13.73% YoY) and the FY2025 annual result came in at $89.9 million, up 17.77% from the prior year.
• Total Liabilities eased to $85.5 million in Q1 2026, from $89.9 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $94.5 million in Q4 2023 to a low of $53.9 million in Q1 2022.
• A 5-year average of $79.7 million and a median of $79.6 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities tumbled 31.86% — and 2023, when it surged 41.53%.
• Tracing BDSX's Total Liabilities over 5 years: stood at $72.3 million in 2022, then jumped by 30.73% to $94.5 million in 2023, then retreated by 19.2% to $76.4 million in 2024, then rose by 17.77% to $89.9 million in 2025, then dropped by 4.93% to $85.5 million in 2026.
• The last three Total Liabilities figures came in at $85.5 million (Q1 2026), $89.9 million (Q4 2025), and $90.4 million (Q3 2025), per Business Quant data.